sorafenib has been researched along with poloxalene in 1 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (poloxalene) | Trials (poloxalene) | Recent Studies (post-2010) (poloxalene) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 660 | 21 | 149 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cai, S; Chen, L; Gan, H; Li, A; Liang, Y; Liu, X; Sui, X; Tang, X; Wang, D; Wu, B; Zhang, Y; Zou, S | 1 |
1 other study(ies) available for sorafenib and poloxalene
Article | Year |
---|---|
Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Drug Delivery Systems; HeLa Cells; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Nanoparticles; Poloxalene; Polyesters; Sorafenib; Xenograft Model Antitumor Assays | 2018 |